ImCare Biotech is invited to attend the NCI SBIR Workshop on Resources for Accelerating Commercialization. The NCI SBIR Development Center offers a two-day commercialization workshop for current NCI SBIR/STTR awardees. The workshop provides awardees an opportunity to learn how to utilize federal and local resources in order to advance commercialization. The workshop brings together representatives from the FDA, CMS, and BARDA, as well as experts from local and private organizations to share their expertise with attending companies.
-
ImCare Biotech completes the NIH CAP Program. The National Institutes of Health (NIH) Commercialization Accelerator Program (CAP) is a nationwide program funded by NIH and managed by Larta, Inc. The goal of CAP is to assist some of the most promising small life science and healthcare companies in bringing their technologies to market.
-
ImCare Biotech has been awarded Phase II grant by NCI (NIH) for its project on development of a diagnostic kit for early detection of liver cancer.
-
Imcare Biotech has entered into a development partnership with Harvard Medical School.
-
Imcare Biotech has entered into a development partnership with Ohio State University.
-
Imcare Biotech has entered into a development partnership with Thomas Jefferson University.
-
ImCare has developed a new Anti-SPINK1 antibody (BA1), which recognizes native human pancreatic secreted SPINK1/TATI/PSTI in WB and ELISA. More information about this monoclonal antibody and the ELISA kit based on this monoclonal antibody, please contact info@imcarebiotech.com
-
USA patent application 13/991943 Serine Protease Inhibitor Kazal antibodies (Inventor: X. Lu and T. Block) has been filed.
-
A novel technology named Immune-absorbance real time PCR (IA-PCR) with extremely high sensitivity as PCR and great specificity as ELISA has been developed by ImCare Biotech. This technology can be used to quantify any enveloped viruses. Based on this technology, a high-throughput screening system has been established by ImCare Biotech and is successfully used to identify anti-viral drugs.
-
ImCare Biotech has been awarded SBIR grant by NCI (NIH) (National Cancer Institute) to develop its diagonistic kit Seravue® for early detection of liver cancer (HCC and ICC) on 9/2012.